Clinical usefulness of plasma <i>p</i> ‐tau217 and eMTBR‐tau243 combination for diagnosis and patient stratification
Plasma %p-tau217 can rule out Ab-positivity, while eMTBR-tau243 can rule in clinical AD. A two-step model is proposed, with initial testing of %p-tau217 followed by eMTBR-tau243 in %p-tau217-positive patients (Figure 3). This aids in assessing whether AD pathology is either likely to be asymptomatic or is likely to be causing cognitive impairment. MTBR-tau243 may also aid in identifying particularly high tangle burden.
Authors
- Erik Stomrud (ORCID: https://orcid.org/0000-0002-0841-5580)
- Gemma Salvadó (ORCID: https://orcid.org/0000-0002-5210-9230)
- Kanta Horie (ORCID: https://orcid.org/0000-0001-7736-2614)
- Oskar H. Hansson
- Randall J. Bateman
- Sebastian Palmqvist
- Shorena Janelidze
- Nicolas R. Barthélemy
- Suzanne E. Schindler
- Lyduine E. Collij
- Niklas Mattsson‐Carlgren
Institutions
- Lund University (SE)
- Washington University in St. Louis (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_100822
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00